Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 12, 2022

SELL
$1.77 - $3.87 $4,425 - $9,675
-2,500 Closed
0 $0
Q3 2021

Oct 12, 2021

BUY
$5.3 - $7.89 $13,250 - $19,725
2,500 New
2,500 $13,000

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $40.5M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Koshinski Asset Management, Inc. Portfolio

Follow Koshinski Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Koshinski Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Koshinski Asset Management, Inc. with notifications on news.